NEW YORK – JADBio, a Los Angeles-based company specializing in AI, machine learning, and analytics software, said on Thursday that it has entered into a distribution agreement with Qiagen for its JADBio automated machine learning platform.
Under the agreement, Qiagen will sell and distribute the JADBio platform within its Qiagen Digital Insights portfolio. The platform provides AI tools and automation features that enable life science professionals to build and deploy accurate and interpretive predictive models, regardless of their data science expertise, JADBio said.
More specifically, the platform can accept client data or molecular profiles stored in Qiagen's OmicSoft sequencing analysis suite to produce predictive and diagnostic models. Depending on the input data, the models could identify disease or disease subtype; predict response to therapy, time to death, relapse, or metastasis; or produce other outcomes of interest. The company said that its software sorts through hundreds of thousands of omics and clinical markers to identify those that lead to optimal predictions when examined in combination. Results can be fed back to Qiagen's Ingenuity Pathway Analysis and other Qiagen Digital Insight products for further interpretation.
"We welcome this agreement as a crucial development in our quest to make JADBio available to all life science researchers and customers globally," JADBio CEO Ioannis Tsamardinos said in a statement. "Our offering compliments Qiagen's Digital Insights well."
Financial terms of the agreement were not disclosed.